French gene therapy company for ophthalmic diseases: GenSight Biologics (GNST) (2012)

GenSight Biologics SA (NASDAQ: GNST) was founded on April 17, 2012, headquartered in Paris, France, with 18 full-time employees (12/31/2014). It is a clinical stage biotechnology company dedicated to discovering and developing new Drugs and therapies for the treatment of mitochondrial and neurodegenerative diseases of the eye.


July 7, 2015

IPO date

To be determined

GenSight Biologics Logo

GenSight Biologics (GNST):

GenSight Biologics is based on gene therapy, combined with its core mitochondrial targeted sequence technology platform (MTS) and optogenetics, and uses its integrated development platform to solve a series of ophthalmic diseases and central nervous system diseases.

The management and scientific research team of GenSight Biologics has extensive experience in gene therapy and drug development, especially in the field of ophthalmology, and holds leadership positions in some innovative ophthalmology companies.

GenSight currently has two main products, one for the treatment of vision-threatening retinal degenerative diseases, and the other is still in the pre-clinical stage, mainly for the treatment of ophthalmology and neurodegenerative diseases.

GenSight Biologics (GNST) investment:

The company submitted its IPO prospectus on 7/7/2015 and plans to raise 100 million US dollars. It is traded on Nasdaq under the stock code: GNST.

GenSight official website:

GenSight American Stock Encyclopedia:

Notify of
Inline Feedbacks
View all Intels

China Stocks: Niu Technologies (NIU), a provider of smart city travel tools

Brazilian Airlines: Lemo Air China Gol Linhas Aéreas Inteligentes (GOL) (2001)